Successful use of intraventricular and intravenous rituximab therapy for refractory primary CNS lymphoma in a child

Intra-CSF administration of chemotherapy medications

“…Rituximab has been used for the treatment of relapsed or refractory CNS lymphomas. Most patients achieved a partial or complete remission as described in available case reports [63][64][65][66][67][68][69][70][71][72][73][74]. For both of these agents, dose and duration of treatment were variable.…”

“…Two case reports described use of intrathecal rituximab in pediatric patients [73,74]. Akyuz reported successful use of rituximab in a 14-year-old patient with refractory primary CNS lymphoma [73]. The dose ranged from 10 to 35 mg given via an Ommaya reservoir.…”

“…Most patients had received extensive chemotherapy (systemic or intrathecal) prior to and after completion of intrathecal rituximab. Two case reports described use of intrathecal rituximab in pediatric patients [73,74]. Akyuz reported successful use of rituximab in a 14-year-old patient with refractory primary CNS lymphoma [73].…”

Role of Intrathecal Rituximab and Trastuzumab in the Management of Leptomeningeal Carcinomatosis

“…Cytologic responses were also accompanied with symptomatic improvements in 4 cases and included neurologic improvements, disappearance of seizures and headaches, and cognitive improvement. 24,25,27,28 Only 1 report described progression of CNS lymphoma. 26 Survival in these 7 case reports ranged from 4 months to greater than 3.5 years.…”

“…[23][24][25][26][27][28][29] Doses ranged from 10 to 40 mg and were most commonly initiated at 10 mg and increased to the highest tolerated dose or until acceptable clinical response occurred. All 7 patients showed response in tumor cell clearance.…”